Welcome to our dedicated page for The Oncology Institute news (Ticker: TOIIW), a resource for investors and traders seeking the latest updates and insights on The Oncology Institute stock.
The Oncology Institute Inc (NASDAQ: TOIIW) delivers community-focused cancer care through innovative value-based models and clinical research integration. This news hub provides investors and healthcare professionals with essential updates on operational developments, strategic partnerships, and patient care advancements.
Access authoritative reporting on TOI's financial performance, clinical trial milestones, and service expansions. Our curated collection includes press releases covering earnings announcements, new clinic openings, research collaborations, and healthcare policy impacts relevant to oncology care delivery.
Key updates feature developments in infusion center operations, progress in value-based payment models, and community health initiatives. Stay informed about TOI's role in outpatient cancer treatment innovation and its growing network of care centers across strategic regions.
Bookmark this page for real-time access to verified TOIIW disclosures and analysis-free reporting. Check regularly for essential updates that matter to stakeholders in oncology care and value-driven healthcare investments.
The Oncology Institute (NASDAQ: TOI) reported record revenue of $203 million for 2021, reflecting an 8.3% increase year-over-year.
For Q4, revenue reached $52 million, a 6.8% increase, despite a net loss of $10 million and significant SG&A expenses of $48 million due to growth investments.
Looking ahead to 2022, TOI anticipates revenue of $270 million to $310 million and projects managing between 1.75 million to 2.0 million lives under value-based contracts.
CERRITOS, Calif., March 8, 2022 – The Oncology Institute of Hope and Innovation (NASDAQ: TOI) announced that CEO Brad Hively will participate in the Jefferies Value-Based Healthcare Summit in Miami on March 14 at 1:40 pm EST. Hively has over 20 years of healthcare experience, transforming TOI into a leading oncology provider with over 50 clinics nationwide. The institute offers innovative, value-based cancer care to approximately 1.6 million patients. Investors can access a webcast of the event on the company’s website.
The Oncology Institute of Hope and Innovation (NASDAQ: TOI) has announced the promotions of Dr. Daniel Virnich to President and Dr. Matt Miller to Chief Operating Officer, effective March 15, 2022. These changes are part of a response to TOI's rapid growth. Dr. Virnich, who joined in 2020, will oversee various functions including Operations and Compliance, while Dr. Miller will manage all field and central operations nationally. Both leaders have previously driven tangible improvements in operational efficiency and patient satisfaction, positioning TOI for continued development in specialized oncology care.
The Oncology Institute (TOI) has established a value-based agreement with MaxHealth to deliver medical oncology care in Pinellas and Hillsborough Counties, beginning March 1, 2022. This partnership aims to enhance patient care through TOI's innovative oncology model, which includes over 170 clinical trials and comprehensive oncology services. The initiative targets expansion into neighboring counties, reflecting TOI's commitment to improving cancer care accessibility. Both organizations emphasize a shared goal of personalized patient care and satisfaction.
The Oncology Institute of Hope and Innovation (TOI) has entered a value-based agreement with MaxHealth to provide medical oncology care in Pinellas and Hillsborough Counties, Florida. This partnership, effective from March 1, 2022, aims to enhance cancer care access and quality through community-focused services, including clinical trials and stem cell transplants. TOI plans to expand this initiative to neighboring counties shortly. Both organizations emphasize a commitment to personalized care and improving patient satisfaction.
The Oncology Institute (TOI) will release its fourth quarter and full year results on March 10, 2022, after market close. Following the results, a conference call is scheduled for 5:00 p.m. ET, accessible via phone or webcast. TOI specializes in delivering advanced, value-based cancer care to over 1.5 million patients, with 54 clinic locations and a team of 80+ clinicians. Their services include clinical trials, stem cell transplants, and transfusions. Interested parties can join the call and access a replay through the provided contact information.
The Oncology Institute of Hope and Innovation (NASDAQ: TOI) has expanded its footprint by opening its 54th clinic in Lakeland, Florida, enhancing oncology services available in Polk County. This new clinic, which is the sixth in Florida, aims to provide patients with convenient access to oral chemotherapeutics and blood transfusion services. With experienced providers onboard, the institute continues to showcase its commitment to value-based cancer care. The expansion aligns with TOI's efforts to elevate healthcare standards and meet growing patient needs in the region.
TOI has expanded its physician network by acquiring the practices of Dr. Ellsworth R. Grant and Dr. Leo E. Orr, adding to its team of over 80 clinicians. This acquisition will enhance TOI's ability to provide value-based oncology care to more than 1.5 million patients across its locations.
The new facility in Westlake offers advanced medical services similar to other TOI clinics, enhancing patient access to high-quality cancer care.
The Oncology Institute (TOI) has successfully completed its business combination with DFP Healthcare Acquisitions Corp., with approval received on November 12, 2021.
This merger, now valued at $842 million, enables TOI to retain approximately $133 million for growth initiatives. TOI’s stock began trading on NASDAQ under the symbols 'TOI' and 'TOIIW'. With a history of providing high-quality cancer care to over 150,000 patients across four states, TOI aims to disrupt the $200 billion U.S. oncology market through a value-based care model.
FAQ
What is the current stock price of The Oncology Institute (TOIIW)?
